Sesen Bio (SESN) Misses Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. TMUS
5. PEP
6. AXP
7. T
8. SPY
9. CVS
10. UNH

Go back to Sesen Bio (SESN) Misses Q3 EPS by 11c

Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the BLA Submission for VicineumTM in December 2020

November 9, 2020 7:30 AM EST

Manufacturing of Vicineum drug substance and drug product PPQ batches has been completed

Emerging manufacturing data provides strong support for analytical comparability between clinical and commercial material

On track to complete BLA submission to the FDA in December 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the third quarter ended September 30, 2020. The Companys... More